Skip to Content

Media Releases

 


Corporate News

20. November 2009
European medical advisory committee does not recommend approval of Avastin for deadly form of brain cancer
Roche announced today that the Committee for Medicinal Products for Human Use (CHMP), which is responsible for conducting ... more

17. October 2009
ACTEMRA inhibits progression of joint destruction in RA patients by over 80% compared to methotrexate alone
Two-year data from the LITHE study, being presented at the American College of Rheumatology, show that, with long-term use, ... more

15. October 2009
Roche reports further accelerated sales growth in third quarter
Group sales up 3.1 billion to 36.4 billion Swiss francs in first nine months, an increase of 11% in local currencies (9% in ... more

24. September 2009
Herceptin provides impressive survival benefit for patients with high levels of HER2 in their stomach cancer
A detailed analysis of the Phase III ToGA study announced today revealed an unprecedented survival benefit for patients whose ... more

24. September 2009
Continuous improvements in animal welfare within Roche Research
Roche announced the winners of its global 3Rs Award Program - a unique and innovative program that helps to reduce and limit ... more

23. September 2009
From inoperable disease to potentially life saving surgery - new Avastin data gives hope to colorectal cancer patients with liver metastases
New data from several studies presented at ECCO 15 and ESMO 34 confirm unique benefits of Avastin (bevacizumab) and Xeloda ... more

23. September 2009
Roche announces results from two early studies which show promise for patients with malignant melanoma
New data from phase II Avastin study and a phase I extension study of highly selective BRAF inhibitor more

22. September 2009
Avastin could play an important role in improving the daily lives of patients with the most aggressive form of brain cancer
Analysis of BRAIN study shows that patients may have a stabilisation or improvement in neurocognitive function and a reduction ... more

13. September 2009
Two new studies report increased survival rates in Tamiflu-treated patients with avian flu (H5N1) and severe seasonal flu
53% of patients with H5N1 infection survived when treated with Tamiflu compared with 12% of untreated patients. Rate of death ... more

08. September 2009
Roche announces new Corporate Executive Committee
William M. Burns, Juergen Schwiezer and Jonathan Knowles to retire – Pascal Soriot appointed COO Pharma Division and ... more

03. September 2009
Roche recognised as new Super Sector Leader in Dow Jones Sustainability Index
Roche has been rated as the new Super Sector Leader in Healthcare on the Dow Jones Sustainability Index, placing Roche as ... more

03. September 2009
MabThera approved in Europe for use in patients with previously-treated chronic lymphocytic leukaemia
Roche announced today that the European Commission has approved MabThera (rituximab) for use in patients with relapsed or ... more

01. September 2009
Roche receives CE Mark certification for cobas 8000 modular analyzer series
Roche announced today that the CE Mark certification for cobas 8000 modular analyzer series has been granted allowing commercial ... more

18. August 2009
Avastin plus commonly used chemotherapies improves time without the disease getting worse in women with previously treated advanced breast cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a Phase III study of Avastin (bevacizumab) in combination with a range ... more

05. August 2009
Roche Continents takes place for the third time
For the third time, Roche and the Salzburg Festival have invited 100 students to take part in "Roche Continents". ... more

03. August 2009
Avastin approved in US for the most common type of kidney cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin (bevacizumab) plus interferon ... more

30. July 2009
Second Phase III Study Showed Lucentis Improved Vision in Patients with Retinal Vein Occlusion
Roche announced today that the Phase III study CRUISE showed Lucentis (ranibizumab injection) improved vision in patients ... more

29. July 2009
European commission approves broader label for Avastin allowing combination with docetaxel for the first-line treatment of advanced (metastatic) breast cancer
Physicians will be able to offer more patients Avastin-based treatment options more

24. July 2009
MabThera receives positive opinion in Europe for treating patients whose chronic lymphocytic leukaemia returns
Roche announced today that the European Union’s Committee on Human Medicinal Products (CHMP) has issued a positive recommendation ... more

23. July 2009
Double-digit increase in sales, operating profit and Core EPS
Integration of Genentech progressing rapidly; full-year outlook raised; Group sales up 2 billion to 24 billion Swiss francs, ... more

20. July 2009
Xeloda in combination with oxaliplatin shown to be effective in early colon cancer
Roche announced today results from the international phase III study NO16968 (XELOXA), investigating oral Xeloda in combination ... more

13. July 2009
New data from phase III SATURN study shows Tarceva improves overall survival when used immediately after initial chemotherapy in patients with advanced lung cancer
Roche announced today that SATURN, a pivotal Phase III study, met a key secondary endpoint of extending overall survival in ... more

02. July 2009
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
Roche announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured ... more

01. July 2009
Roche launches novel program to ease Tamiflu access to developing economies
Roche today announced the initiation of the Tamiflu Reserves Program (TRP) for developing economies. The program, which is ... more

11. June 2009
New data demonstrate the ability of MabThera to reduce the progression of joint damage when used as a first-line biologic treatment in rheumatoid arthritis
RA patients with enhanced response identified more

10. June 2009
New data reinforces long-term efficacy of ACTEMRA in rheumatoid arthritis across all patient population types
Up to 56% of patients with active rheumatoid arthritis (RA) treated with ACTEMRA (tocilizumab, known as RoACTEMRA within the ... more

09. June 2009
Roche to commence phase III trials with innovative treatment designed to lower cardiovascular risk in diabetes patients with recent heart attack
Roche today announced it will start Phase III clinical investigations for aleglitazar, its innovative PPAR co-agonist R1439 ... more

01. June 2009
Encouraging first data on new targeted treatment for patients with melanoma - the deadliest form of skin cancer
Roche announced today results from a phase I study with PLX4032 (R7204) a new, highly selective and promising treatment for ... more

31. May 2009
Herceptin landmark study (ToGA) reveals unprecedented survival benefit in HER2-positive stomach cancer
Data from the ToGA study presented today at the American Society for Clinical Oncology Annual Meeting in Orlando, Florida ... more

30. May 2009
Maintenance treatment with Avastin and Tarceva in combination helps lung cancer patients live longer without their disease worsening
Phase III ATLAS study achieves a new milestone in treating advanced lung cancer more

30. May 2009
Full results from first Phase III study of Avastin in adjuvant colon cancer announced
Results suggest future trials may hold promise for Avastin as early-stage colon cancer treatment even though C-08 study does ... more

25. May 2009
Two-year data reinforce effectiveness of ACTEMRA in inhibiting joint damage and improving physical function in patients with rheumatoid arthritis
Roche announced today that new two-year data from the LITHE study demonstrate that ACTEMRA (tocilizumab, known as RoACTEMRA ... more

15. May 2009
Roche to present major advances with targeted cancer medicines at ASCO
More than 500 scientific abstracts to be presented across 20 types of cancers. Results could significantly improve the way ... more

12. May 2009
Roche provides additional donation of 5.65 million packs of Tamiflu to World Health Organization
Roche today announced a new donation to the World Health Organization (WHO) of 5.65 million courses of treatment of the antiviral ... more

06. May 2009
Important New Treatment Option Approved in US for Patients with the Most Aggressive Form of Brain Cancer
Roche today announced that the US Food and Drug Administration (FDA) granted accelerated approval of Avastin (bevacizumab) ... more

02. May 2009
Roche rapidly responds to WHO request to deploy Rapid Response Stockpiles of Tamiflu to tackle global emergence of a new H1N1 influenza A strain - swine flu
Roche today confirms that the World Health Organisation (WHO) has requested deployment of the “Rapid Response Stockpile.” ... more

30. April 2009
Roche responds to WHO move to influenza pandemic alert phase 5
Roche tonight confirms that it has been in contact with the World Health Organization (WHO) following the announcement to ... more

29. April 2009
Roche steps up preparedness level in response to WHO's increase to pandemic alert phase 4
Roche today confirms that it is working closely with the World Health Organization (WHO) and Governments around the world ... more

22. April 2009
Phase III C-08 study of Avastin in early-stage colon cancer does not meet primary endpoint
Roche today announced the results of the first phase III trial evaluating the use of Avastin (bevacizumab) plus chemotherapy ... more

16. April 2009
Roche strongly outperforms market in first quarter
Group sales up 8% in local currencies and 7% in Swiss francs to 11.6 billion Swiss francs (-1% in US dollars); Roche completes ... more

15. April 2009
Roche Diabetes Care supports "Changing Diabetes in Children"
Roche today announced that it will join forces with Novo Nordisk and the World Diabetes Foundation (WDF) in Novo Nordisk’s ... more

14. April 2009
Roche and Genentech announce organizational and leadership decisions
Following the completion of the Genentech transaction Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) today announced the successful ... more

02. April 2009
Roche to introduce new LightCycler MRSA Advanced Test in the EU
Roche announced today that its new LightCycler test for the detection of methicillin-resistant Staphylococcus aureus (MRSA) ... more

26. March 2009
Roche completes acquisition of Genentech
Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) and Genentech (NYSE: DNA) announced today that Roche has completed its acquisition ... more

26. March 2009
Roche completes tender offer for Genentech
Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) announced today that its wholly-owned subsidiary, Roche Investments USA Inc., completed ... more

18. March 2009
Herceptin now shown to significantly prolong the lives of patients with HER2-positive advanced stomach cancer
Roche today announced results from a major international study which show that adding Herceptin (trastuzumab) to standard ... more

16. March 2009
Roche acquires innovatis AG to complement its product portfolio in the rapidly growing area of cellular analytics
Roche today announced that it has signed a definite agreement under which Roche will acquire 100% of innovatis, a privately ... more

12. March 2009
Roche and Genentech reach a friendly agreement to combine the two organizations and create a leader in healthcare innovation
Roche (SWX: ROG.VX; RO.S) and Genentech (NYSE: DNA) announced today that they signed a merger agreement under which Roche ... more

11. March 2009
Herceptin proven to benefit women with HER2 positive early breast cancer - latest results from the HERA study
The Breast International Group (BIG) in collaboration with Roche announced today that women with HER2 positive early breast ... more

10. March 2009
Roche Annual General Meeting: dividend raised by 9 percent
Roche's Annual General Meeting, which was held today in Basel, has approved all the Board of Directors' proposals. ... more

06. March 2009
Roche increases offer price for Genentech shares to US$ 93 per share and extends offer
Roche (SWX: ROG.VX; RO.S) announced today that it has increased its offer price for all outstanding publicly-held shares of ... more

27. February 2009
MabThera approved in the EU for patients with chronic lymphocytic leukaemia
Roche announced today that the European Commission has approved MabThera (rituximab) in combination with chemotherapy for ... more

16. February 2009
For the first time, doctors can predict which hepatitis B patients have the highest chance to achieve treatment success with Pegasys
New data presented today showed that, for the first time, doctors can predict which hepatitis B patients treated with Pegasys ... more

09. February 2009
Roche commences tender offer for Genentech for US$86.50 per share in cash
Roche announced today that it is commencing a cash tender offer for all outstanding publicly-held shares of Genentech for ... more

04. February 2009
Strong operating results for Roche in 2008
Double-digit sales growth - Core Earnings per share at constant exchange rates above 2007 level - Dividend increase by 9% to 5.00 Swiss francs proposed more

03. February 2009
Avastin and Tarceva in combination significantly improves the time patients with advanced lung cancer can live without their disease worsening
Roche today announced interim results from a phase III study (ATLAS) in patients with advanced non small cell lung cancer ... more

30. January 2009
Roche intends to commence tender offer to acquire all shares of Genentech for US$ 86.50 per share in cash
Roche announced today that it intends to commence a cash tender offer for all outstanding publicly-held shares of Genentech ... more

28. January 2009
Roche delighted about pool extension
Roche’s Board of Directors and Corporate Executive Committee is delighted about the extension of the shareholders’ ... more

23. January 2009
Foundation-laying ceremony for new R&D building at Roche Basel
At a ceremony attended by people involved in the project and other guests, the foundation stone was laid today for the new ... more

23. January 2009
MabThera receives positive opinion in Europe for first-line treatment for chronic lymphocytic leukaemia
Roche announced today that the European Union’s Committee on Human Medicinal Products (CHMP) has issued a positive recommendation ... more

21. January 2009
RoACTEMRA approved in Europe to treat patients suffering from Rheumatoid Arthritis
Roche today announced that the European Commission has approved RoACTEMRA (tocilizumab, known as Actemra outside of the EU), ... more

Trade News